Does COVİD-19 m-RNA Vaccine Affect Fertility and Over Reserve ?

Sponsor
Gaziosmanpasa Research and Education Hospital (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05489367
Collaborator
(none)
64
1
9.9
6.5

Study Details

Study Description

Brief Summary

Women's ovarian reserve and fertility were compared before and after 2 doses of vaccination

Condition or Disease Intervention/Treatment Phase
  • Biological: sars cov 2 biontec vaccine

Detailed Description

our study ıs desıgned as an observatıonal clınıcal study. the purpose ıs to compare the over reserve tests of the patıents before and after vaccıne, to determıne ıf the over reserve and fertılıty of women are affected by the vaccıne.women who applied to the vaccination outpatient clinic for the first dose of vaccine were included in the study.those who have never been vaccinated and have not had covid 19 infection were included in the study.antı ullerıan hormone level ıs the laboratory parameters that best showıng the ovary reserve today. ovarian reserve tests including amh were checked and their fertility was questioned and their information was recorded.

the same tests were repeated after the volunteers received 2 doses of vaccine. ın the power analysis, it was calculated that 104 volunteers should be included in the study.the study will be terminated when 104 volunteers are reached.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
64 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Does COVİD-19 m-RNA Vaccine Affect Fertility and Over Reserve ?
Actual Study Start Date :
Feb 1, 2022
Anticipated Primary Completion Date :
Oct 20, 2022
Anticipated Study Completion Date :
Nov 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Pre-vaccine ovarian reserve and fertility status

Before vaccination, ovarian reserve tests and fertility status of 64 women will be examined and results will be recorded.After 2 doses of vaccination, ovarian reserve and fertility status of same 64 women will be examined and results will be recorded

Biological: sars cov 2 biontec vaccine
volunteers will be expected to receive 2 doses of vaccine

Outcome Measures

Primary Outcome Measures

  1. Ovarian reserve tests and fertility status of 74 women before and after vaccination [6 months after receiving the 2nd dose of vaccine]

    before and after vaccination serum Amh level ng/ml

Secondary Outcome Measures

  1. AMH difference between vaccinated and unvaccinated groups [6 months]

    AMH difference between vaccinated and unvaccinated groups

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • between 18-45 years old

  • have ever had a covid vaccine

  • not be infected with covid 19

Exclusion Criteria:
  • pregnancy

  • diagnosis of any kind of cancer

  • oral contraceptive usage

  • endometrioma

  • PCOS

  • menopause

  • menstrual irregularity

  • premature ovarian insufficiency

Contacts and Locations

Locations

Site City State Country Postal Code
1 Gaziosmanpasa Training and Research Hospital Istanbul Gaziosmanpaşa Turkey 32225

Sponsors and Collaborators

  • Gaziosmanpasa Research and Education Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Elif Yıldız, DOCTOR, Gaziosmanpasa Research and Education Hospital
ClinicalTrials.gov Identifier:
NCT05489367
Other Study ID Numbers:
  • GaziosmanpasaTREHm
First Posted:
Aug 5, 2022
Last Update Posted:
Aug 5, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Keywords provided by Elif Yıldız, DOCTOR, Gaziosmanpasa Research and Education Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 5, 2022